切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2016, Vol. 10 ›› Issue (02) : 71 -75. doi: 10.3877/cma.j.issn.1674-0807.2016.02.002

论著

不同激素受体状态乳腺癌趋化因子CCL5 的表达及临床意义
朱永云1,†(), 李娟娟2, 陈创2, 赵迎春1   
  1. 1.241000 芜湖市第二人民医院甲状腺乳腺外科
    2.400060 武汉大学人民医院乳腺甲状腺外科
  • 收稿日期:2015-06-08 出版日期:2016-04-01
  • 通信作者: 朱永云
  • 基金资助:
    国家自然科学基金青年基金资助项目(81302314)

Expression of chemokine CCL5 in breast cancer with different hormone receptor status and its clinical significance

Yongyun Zhu1,†(), Juanjuan Li2, Chuang Chen2, Yingchun Zhao1   

  1. 1.Department of Thyroid and Breast Surgery, Wuhu Second People's Hospital, Wuhu 241000, China
    2.Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China
  • Received:2015-06-08 Published:2016-04-01
  • Corresponding author: Yongyun Zhu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

朱永云, 李娟娟, 陈创, 赵迎春. 不同激素受体状态乳腺癌趋化因子CCL5 的表达及临床意义[J/OL]. 中华乳腺病杂志(电子版), 2016, 10(02): 71-75.

Yongyun Zhu, Juanjuan Li, Chuang Chen, Yingchun Zhao. Expression of chemokine CCL5 in breast cancer with different hormone receptor status and its clinical significance[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2016, 10(02): 71-75.

目的

探讨不同激素受体状态乳腺癌组织中趋化因子CCL5 表达的临床意义。

方法

应用免疫组织化学SP 法检测2008年1月至2010年1月芜湖市第二人民医院121 例浸润性乳腺癌手术患者组织石蜡样本中CCL5 的表达,采用χ2 检验分析CCL5 与临床病理因素关系,并运用单因素和多因素生存分析不同激素受体状态乳腺癌组织中CCL5 表达的预测价值。

结果

乳腺癌组织中CCL5 表达与淋巴结状态有关(χ2=18.676,P＜0.001)。 CCL5 阳性组的5年DFS 显著低于CCL5 阴性组(χ2=5.089,P=0.024),淋巴结状态阳性组的5-DFS 显著低于淋巴结状态阴性组(χ2=26.105,P＜0.001)。 进一步多因素分析显示,淋巴结状态是乳腺癌患者5年DFS 的独立预后因素(RR=5.453,95%CI:2.589 ～11.485,P＜0.001)。 激素受体阳性患者中,CCL5 阳性组的5年DFS 显著低于CCL5 阴性组(χ2 =10.535,P=0.001),淋巴结状态阳性组的5年DFS 显著低于淋巴结状态阴性组(χ2 =11.439,P=0.001),不同组织学分级组患者间5年DFS 差异具有统计学意义(χ2=6.024,P=0.049),进一步多因素分析显示,CCL5 是激素受体阳性乳腺癌患者5年DFS 的独立预后因素(RR=3.205,95%CI:1.052 ～9.762,P=0.040),淋巴结状态是激素受体阳性乳腺癌患者5年DFS 的独立预后因素(RR=3.915,95%CI:1.191 ～12.872, P=0.025)。

结论

不同激素受体状态乳腺癌组织中CCL5 的表达,能为乳腺癌内分泌治疗提供更准确诊疗依据。

关键词: 乳腺肿瘤, 趋化因子CCL5, 预后

Objective

To investigate the expression of chemokine CCL5 in breast cancer with different hormone receptor status and its clinical significance.

Methods

The expression of CCL5 in paraffin-embedded samples was analyzed in 121 cases of invasive breast cancer treated in Wuhu Second People's Hospital from January 2008 to January 2010 using immunohistochemical SP technique. χ2 test was used to detect the relationship between CCL5 expression and clinicopathologic parameters. The survival analysis was used to detect the prognostic value of CCL5 in breast cancer tissue with different hormone receptor status.

Results

CCL5 expression in breast cancer tissue was related to lymph node status (χ2=18.676,P＜0.001).The 5-year DFS in CCL5 positive group was significantly lower than that in CCL5 negative group (χ2=5.089,P=0.024);the 5-year DFS in positive lymph node group was significantly lower than that in negative lymph node group(χ2=26.105, P ＜0.001). The multivariate analysis showed that lymph node status was an independent prognostic factor for 5-year DFS of breast cancer patients (RR=5.453,95%CI:2.589-11.485, P＜0.001).In the patients with hormone receptor positive, the 5-year DFS in CCL5 positive group was significantly lower than that in CCL5 negative group (χ2 =10.535,P=0.001); the 5-year DFS in positive lymph node group was significantly lower than that in negative lymph node group (χ2=11.439,P＜0.001); the 5-year DFS showed a significant difference among the patients with breast cancer of different histological grades (χ2 =6.024,P=0.049). CCL5 and lymph node status were independent prognostic factors for 5-year DFS in patients with hormone receptor positive breast cancer (RR=3.205,95%CI:1.052-9.762,P=0.040;RR=3.915,95%CI:1.191-12.872, P=0.025).

Conclusion

CCL5 expression in breast cancer tissue with different hormone receptor status can provide important reference in clinical management of breast cancer.

Key words: Breast neoplasms, Chemokine CCL5, Prognosis
图1 乳腺癌组织中趋化因子CCL5 的表达(SP ×200) 注:a 图所示CCL5 的阳性表达;b 图所示CCL5 的阴性表达
表1 乳腺癌患者生存资料变量赋值表
变量 变量分类及赋值
年龄 ≤50岁=0,＞50岁=1
淋巴结状态 阴性=0,阳性=1
肿瘤大小 ≤2 cm=0,＞2 cm=1
组织学分级 1级=1,2级=2,3级=3
激素受体状态 阴性=0,阳性=1
HER-2状态 阴性=0,阳性=1
复发 未复发=0,复发=1
表2 121 例乳腺癌患者的临床病理特征与趋化因子CCL5 表达关系
项目 总例数 CCL5阳性(%) χ2值 P值
年龄(岁)
≤50 64 33(51.6) 2.644 0.104
＞50 57 21(36.8)
淋巴结状态
阴性 75 22(18.2) 18.676 ＜0.001
阳性 46 32(69.6)
肿瘤大小
≤2 cm 49 17(34.7) 3.289 0.070
＞2 cm 72 37(51.4)
组织学分级
1级 42 14(33.3) 5.286 0.071
2级 55 25(45.6)
3级 24 15(62.5)
激素受体a
阴性 75 34(45.3) 0.040 0.842
阳性 46 20(43.5)
HER-2
阴性 76 29(38.2) 3.462 0.063
阳性 45 25(55.6)
图2 121 例乳腺癌患者中不同CCL5 状态组间5年无瘤生存曲线 注:组间比较,χ2=5.089,P=0.024
图3 121 例乳腺癌患者中不同淋巴结状态组间5年无瘤生存曲线 注:组间比较,χ2=26.105,P＜0.001
图4 46 例激素受体阳性乳腺癌患者中不同CCL5状态组间5年无瘤生存曲线 注:组间比较,χ2=10.535,P＜0.001
图5 46 例激素受体阳性乳腺癌患者中不同淋巴结状态组间5年无瘤生存曲线 注:组间比较,χ2=11.439,P＜0.001
图6 46 例激素受体阳性乳腺癌患者中不同组织学分级组间5年无瘤生存曲线 注:组间比较,χ2=6.024,P=0.049
[1]
Benson JR, Jatoi I, Keisch M, et al. Early breast cancer[J].Lancet,2009,373(9673):1463-1479.
[2]
Barmes DM, Hanby AM. Destrogen and progesterone receptors in breast cancer:past,present and future[J]. Histopathology,2001,38(3):271-274.
[3]
Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumor stroma promote breast cancer metastasis[J]. Nature,2007,449(7162):557-563.
[4]
Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy[J]. Nat Rev Clin Oncol,2010,7(12):725-732.
[5]
Tripathy D. Are we hitting the right combination for hormonally sensitive breast cancer? [J]. J Clin Oncol,2009,27(16):2580-2582.
[6]
Li J, Tu Y, Wen J, et al. Role for ezrin in breast cancer cell chemotaxis to CCL5[J]. Oncol Rep, 2010,24(4):965-971.
[7]
Gallo M, De Luca A, Lamura L, et al. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells:implications for adjuvant therapy of breast cancer[J]. Ann Oncol,2012,23(3):597-604.
[8]
Svensson S, Abrahamsson A, Rodriguez GV,et al. CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancer[J].Clin Cancer Res,2015, 21(16):3794-3805..
[9]
Soria G, Ofri-Shahak M, Haas I, et al. Inflammatory mediators in breast cancer: coordinated expression if TNFα & IL-1β with CCL2&CCL5 and effects on epithelial-to-mesenchymal transition[J].BMC Cancer,2011,11,130.
[10]
Niwa Y, Akamaksu H, Niwa H, et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer[J]. Clin Cancer Res,2001,7(2):285-289.
[11]
Pinilla S, Alt E, Abdul Khalek FJ, et al. Tissue resident stem cells produce CCl5 under the influence of cancer cells and thereby promote breast cancer cell invasion[J]. Cancer Lett,2009,284(1):80-85.
[12]
Wang Z, Han J, Cui Y, et al. miRNA-21 inhibition enhances RANTES and IP-10 release in MCF-7 via PIAS3 and STAT3 signalling and causes increased lymphocyte migration[J]. Biochem Biophys Res Commun, 2013,439(3):384-389.
[13]
Hartmann MC,Dwyer RM,Costello M,et al. Relationship between CCL5 and transforming growth factor-beta1 (TGFbeta1) in breast cancer[J]. Eur J Cancer,2011,47(11):1669-1675.
[14]
姚晓莉,童鹤翔,涂毅,等. CCL5 及其受体在乳腺癌组织中的表达及其意义[J].中华实验外科杂志,2007,24(5):590-592.
[15]
Yaal-Hahoshen N, Shina S, Leider-Trejo L, et al. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage Ⅱbreast cancer patients[J]. Clin Cancer Res,2006,12(15):4474-4480.
[16]
Dorjgochoo T, Zheng Y, Gao YT, et al. No association between genetic variants in angiogenesis and inflammation pathway genes and breast cancer survival among Chinese women[J]. Cancer Epidemiol,2013,37(5):619-624.
[1] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[2] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[3] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[6] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[7] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[8] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[12] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[13] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[14] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号